Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Four-Part, Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Adults With Moderate to Severe Pachyonychia Congenita

Trial Profile

A Multicenter, Four-Part, Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Adults With Moderate to Severe Pachyonychia Congenita

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 13 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Pachyonychia congenita
  • Focus Registrational; Therapeutic Use
  • Acronyms VALO
  • Sponsors Palvella Therapeutics
  • Most Recent Events

    • 13 Nov 2019 According to a Palvella Therapeutics media release, the company is currently enrolling patients at nine sites across the US and data from this trial is expected in the second half of 2020.
    • 13 Nov 2019 According to a Palvella Therapeutics media release, the company has commenced phase 3 portion of this trial.
    • 12 Mar 2019 Status changed from planning to recruiting, according to a Ligand pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top